18 completed, 9 terminated, 5 withdrawn, 4 active not recruiting. 43 Phase 2, 8 Phase 3, 3 Phase 1.
Follow Corticosteroids: new trials by email Literature Review of Corticosteroids trials Research Report on Corticosteroids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis Etrasimod, Placebo, Corticosteroids - Immune Checkpoint Inhibitor-Related Diarrhea and Colitis | Phase 2 | Withdrawn | Yale University | 2026-01-01 | 2026-01-14 | |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) Ruxolitinib, Corticosteroids - GVHD,Acute, Stem Cell Transplant Complications | Phase 2 | Recruiting | Daihong Liu | 168 | 2025-06-01 | 2026-01-14 |
| Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants MDR-102, Immunosuppressive Agents - Kidney Transplant Rejection | Phase 2 / Phase 3 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Axatilimab, Ruxolitinib, Corticosteroids - Chronic Graft-versus-host-disease | Phase 2 | Active not recruiting | Incyte Corporation | 130 | 2024-10-11 | 2026-10-15 |
| A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids - Graft Versus Host Disease, Acute | Phase 2 | Terminated | Cynata Therapeutics Limited | 65 | 2024-03-04 | 2026-10-22 |
| A Study of TCD601 in de Novo Renal Transplant Recipients TCD601, belatacept, ATG - Renal Transplantation | Phase 2 | Completed | ITB-Med LLC | 76 | 2023-12-28 | 2026-05-05 |
| Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids - Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 10 | 2023-06-05 | 2026-03-24 |
| A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation TCD601, Cyclophosphamide, TAC - Liver Transplantation | Phase 2 | Active not recruiting | ITB-Med LLC | 12 | 2022-06-29 | 2024-11-27 |
| BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar - Transplant Rejection | Phase 2 | Active not recruiting | Sanofi | 48 | 2022-06-09 | 2026-08-21 |
| Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis Mycophenolate Mofetil, Solu-Medrol, Ursodeoxycholic acid - Hepatitis, Drug-Induced | Phase 2 | Unknown | Inge Marie Svane | 60 | 2021-04-07 | 2022-12-14 |
| Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Itacitinib, Corticosteroids - Acute Graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 2 | 2019-12-31 | 2025-11-04 |
| Evaluation of Lycopene in the Treatment of Erosive Oral Lichen Planus Lycopene Softgel, 10 Mg, Prednisolone - Erosive Lichen Planus | Phase 2 / Phase 3 | Completed | Nourhan M.Aly | 20 | 2018-10-01 | 2020-12-03 |
| A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease Methoxsalen + ECP device, Corticosteroids - Acute-graft-versus-host Disease | Phase 2 | Unknown | Central Hospital, Nancy, France | 78 | 2018-10-01 | 2018-07-30 |
| The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients Thymoglobulin, Mycophenolate Mofetil, Tacrolimus - Heart Transplantation | Phase 2 | Enrolling by invitation | Cedars-Sinai Medical Center | 60 | 2018-09-13 | 2026-01-14 |
| Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases bevacizumab, corticosteroids, placebo - Radionecrosis, Brain Metastases | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 19 | 2016-04-01 | 2023-03-23 |
| Regimen Optimization Study Thymoglobulin, Belatacept, mycophenolate mofetil(MMF) - Kidney Transplantation | Phase 2 | Completed | Bristol-Myers Squibb | 58 | 2015-12-31 | 2021-06-22 |
| A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma LABA, corticosteroids, prednisolone - Asthma | Phase 2 | Completed | Hoffmann-La Roche | 54 | 2013-07-01 | 2016-11-02 |
| Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis corticosteroids - Acute Severe Colitis (ASC) | Phase 1 / Phase 2 | Unknown | Jinling Hospital, China | 117 | 2013-01-01 | 2016-10-24 |
Showing 20 of 43. Sign in to see all of them.
Graft vs Host Disease (3) · Leprosy (3) · Colitis (2) · Hepatitis (2) · Lupus Erythematosus, Systemic (2) · Lupus Nephritis (2) · Rejection, Psychology (2) · Arthritis, Rheumatoid (1) · Asthma (1) · Brain Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Chemical and Drug Induced Liver Injury (1) · Demyelinating Diseases (1) · Diabetes Mellitus, Type 1 (1) · Factor 8 deficiency, acquired (1)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Genentech, Inc. (3) · London School of Hygiene and Tropical Medicine (3) · Bristol-Myers Squibb (2) · Hoffmann-La Roche (2) · ITB-Med LLC (2) · Incyte Corporation (2) · Alliance for Clinical Trials in Oncology (1) · Astellas Pharma Inc (1) · Bambino Gesù Hospital and Research Institute (1) · Cedars-Sinai Medical Center (1) · Central Hospital, Nancy, France (1) · Cynata Therapeutics Limited (1) · Daihong Liu (1) · EMD Serono (1)
United States (23) · France (6) · Italy (5) · Canada (4) · Germany (4) · Spain (4) · China (3) · Ethiopia (3) · United Kingdom (3) · Czechia (2) · Denmark (2) · Sweden (2) · Argentina (1) · Australia (1) · Austria (1)
Abraham Shaked, MD, PhD (1) · Aliaa A Bedeir, BDS (1) · Ann Traynor, MD (1) · Azza M Zaki, PhD (1) · Ben Cosimi, MD (1) · Betty Diamond, MD (1) · Bevra Hahn, MD (1) · Caroline Chung, MD (1) · Craig Kessler, MD (1) · David Sachs, MD (1) · Diana Lockwood, MBChB (1) · Diana NJ Lockwood, MBChB (1) · Diana NJ Lockwood, MBchB (1)
PMID 12176626, PMID 12176628, PMID 15233820, PMID 18050221, PMID 22325903, PMID 22946986, PMID 23656665, PMID 26369526, PMID 26472752, PMID 28864814, PMID 29507942, PMID 30506630, PMID 30940770, PMID 33979314, PMID 35332298, PMID 41060318, PMID 41786454
2009 (1), 2017 (1), 2018 (1), 2023 (1), 2025 (1)